Torch

• Research type

  Research Study

• Full title

  Torch: A phase II study to determine the safety and efficacy of the dual mTORC inhibitor AZD2014 and to investigate additional toxicities in combination with rituximab in relapsed refractory DLBCL

• IRAS ID

  173699

• Contact name

  Godwill Iheagwaram Iheagwaram

• Contact email

  Torch@trials.bham.ac.uk

• Eudract number

  2014-003588-39

• Duration of Study in the UK

  3 years, 6 months, 2 days

• Research summary

  The aim of this clinical trial is to see if the drug called AZD2014 is effective and safe to use to treat patients with relasped or refractory Diffuse Large B-Cell Lymphoma (DLBCL). \nWe will also be looking at combining the antibody (Rituximab) with the drug AZD2014 in a small number of patients to see if this can be done without increasing the toxicity.\n36 patients will be recruited to the trial. 30 will recived AZD2014 alone and the remaining 6 will receive AZD2014 plus rituximab. \nAZD2014 will be given as a 125mg tablet that is to be taken twice a day for 2 days out of every 7 (i.e. on days 1 and 2 of every week). Rituximab will be given via IV infusion on day 1 of every 28 days (once every 4 weeks) for a maximum of 6 cycles.

• REC name

  West Midlands - Edgbaston Research Ethics Committee

• REC reference

  15/WM/0126

• Date of REC Opinion

  18 May 2015

• REC opinion

  Further Information Favourable Opinion